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Summary
Background Measuring routine childhood vaccination is crucial to inform global vaccine policies and programme 
implementation, and to track progress towards targets set by the Global Vaccine Action Plan (GVAP) and 
Immunization Agenda 2030. Robust estimates of routine vaccine coverage are needed to identify past successes and 
persistent vulnerabilities. Drawing from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2020, 
Release 1, we did a systematic analysis of global, regional, and national vaccine coverage trends using a statistical 
framework, by vaccine and over time.
Methods For this analysis we collated 55 326 country-specific, cohort-specific, year-specific, vaccine-specific, and dose-
specific observations of routine childhood vaccination coverage between 1980 and 2019. Using spatiotemporal 
Gaussian process regression, we produced location-specific and year-specific estimates of 11 routine childhood 
vaccine coverage indicators for 204 countries and territories from 1980 to 2019, adjusting for biases in country-
reported data and reflecting reported stockouts and supply disruptions. We analysed global and regional trends in 
coverage and numbers of zero-dose children (defined as those who never received a diphtheria-tetanus-pertussis 
[DTP] vaccine dose), progress towards GVAP targets, and the relationship between vaccine coverage and 
sociodemographic development.
Findings By 2019, global coverage of third-dose DTP (DTP3; 81·6% [95% uncertainty interval 80·4–82·7]) more 
than doubled from levels estimated in 1980 (39·9% [37·5–42·1]), as did global coverage of the first-dose measles-
containing vaccine (MCV1; from 38·5% [35·4–41·3] in 1980 to 83·6% [82·3–84·8] in 2019). Third-dose polio 
vaccine (Pol3) coverage also increased, from 42·6% (41·4–44·1) in 1980 to 79·8% (78·4–81·1) in 2019, and global 
coverage of newer vaccines increased rapidly between 2000 and 2019. The global number of zero-dose children fell 
by nearly 75% between 1980 and 2019, from 56·8 million (52·6–60·9) to 14·5 million (13·4–15·9). However, over 
the past decade, global vaccine coverage broadly plateaued; 94 countries and territories recorded decreasing DTP3 
coverage since 2010. Only 11 countries and territories were estimated to have reached the national GVAP target of 
at least 90% coverage for all assessed vaccines in 2019.
Interpretation After achieving large gains in childhood vaccine coverage worldwide, in much of the world this progress 
was stalled or reversed from 2010 to 2019. These findings underscore the importance of revisiting routine 
immunisation strategies and programmatic approaches, recentring service delivery around equity and underserved 
populations. Strengthening vaccine data and monitoring systems is crucial to these pursuits, now and through 
to 2030, to ensure that all children have access to, and can benefit from, lifesaving vaccines.
Funding Bill & Melinda Gates Foundation.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
The development and mass distribution of childhood 
vaccines has been one of the greatest public health 
achievements in history, underpinning marked progress 
in child survival and health outcomes worldwide.1–4 
Initiated by WHO in 1974, the Expanded Programme on 
Immunisation (EPI) spurred coordinated, country-level 
progress in routine vaccination (eg, diphtheria, tetanus, 
pertussis, measles, polio, and BCG), and laid the 
foundation for efforts to introduce new vaccines and 
further increase coverage over the following decades.5 
National govern ments and global organisations continue 
to dedicate substantial resources to vaccines, with total 
spending on immunisation exceeding US$107 billion 
in low-income and middle-income countries alone 
from 2000 to 2017.6 The 2011–20 Global Vaccine Action 
Plan (GVAP) set forth various targets for childhood 
vaccination, such as reaching 90% coverage across all 
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vaccines in national immunisation programmes by 2020.7 
GVAP’s successor, the Immunization Agenda 2030 
(IA2030), further calls for increased and equitable access 
to all routine vaccines for everyone, proposing to halve 
the number of zero-dose children missed by current 
vaccination programmes in each country by 2030.8,9
Yet as the GVAP era ends and IA2030 begins, acute 
service delivery challenges have emerged, with the 
COVID-19 pandemic substantially affecting routine 
immunisation throughout the world in 2020.10–12 At this 
pivotal juncture, it is important to clearly understand 
where—and for which vaccines—gains and gaps in 
coverage occurred before the onset of COVID-19. Robust 
and comparable estimates of vaccine coverage over time 
are thus key inputs for evaluating progress towards GVAP 
targets and serve as a baseline for IA2030’s ambitions.
Vaccination data can be sparse, subject to bias, and 
inconsistent, complicating coverage estimation at both 
national and global levels. Since 2000, the WHO–
UNICEF Estimates of National Immunization Coverage 
(WUENIC)13 have compiled available data sources (ie, 
country-reported data and household surveys gathered 
through the Joint Reporting Form [JRF]) for all member 
states and produced annual coverage estimates, by 
vaccine and dose, based on prespecified heuristics and 
expert judgement.13–15 Although WUENIC’s approach 
has its strengths, such as incorporating qualitative 
knowledge and engagement via country consultation 
processes, statistical models offer import ant advantages. 
For instance, in the WUENIC method, country-reported 
data are only calibrated to survey-based estimates when 
both datapoints are available for a given vaccine-country-
year and a discrepancy of ten percentage points or more 
is observed between survey data and country-reported 
data.15 Statistical models can account more fully for 
trends in reporting bias, as well as synthesise discrepant 
data sources while accounting for data quality and 
precision, quantify uncertainty, and leverage trends in 
time and other predictors to improve estimates where 
data are sparse. Previous research has used statistical 
methods to quantify discrepancies in administrative 
versus survey-based coverage over time;16,17 however, 
such work is generally limited to a subset of vaccines, 
locations, or years. To date, no past research has, to our 
knowledge, systematically estimated coverage across 
vaccines, over multiple decades, and by location for all 
countries within a cohesive statistical modelling 
framework.
Research in context
Evidence before this study
Rigorous, comparable, and timely estimates of vaccine 
coverage are needed to inform vaccination policies, 
programmes, and investments. WHO and UNICEF gather 
country-reported administrative and household survey data 
each year, among other immunisation indicators, through the 
Joint Reporting Form for immunisation, and annually produce 
the WHO–UNICEF Estimates of National Immunization 
Coverage (WUENIC) for member states. This estimation 
process, which has been described as a rule-based approach 
combining heuristics with expert assessment and decisions, 
has some strengths, including familiarity for key stakeholders 
and the ability to integrate expert opinion on vaccine coverage 
and its drivers. Compared to statistical models, however, the 
WUENIC approach does not produce quantitative estimates of 
uncertainty and adjusts only for relatively large discrepancies 
between country-reported data and household survey coverage 
estimates. To the best of our knowledge, no other study 
provides systematic, internally consistent analyses of global, 
regional, and national vaccine coverage trends based on a 
statistical framework, by vaccine and over time.
Added value of this study
Drawing from the Global Burden of Diseases, Injuries, and Risk 
Factors Study (GBD) 2020, Release 1, our analysis provides 
annual estimates of routine vaccine coverage for 11 vaccine-
dose combinations from 1980 to 2019 in 204 countries and 
territories. Our modelling approach incorporates time-varying 
and location-varying bias adjustments, leverages temporal 
trends and covariate relationships to estimate vaccine coverage 
in the absence of country-specific data, and quantifies 
uncertainty for all estimates. We use these coverage estimates 
and GBD population estimates to quantify the number of 
zero-dose children (ie, children who have never received a dose 
of a diphtheria-tetanus-pertussis [DTP] vaccine as a proxy) over 
time; measure progress towards the Global Vaccine Action Plan 
(GVAP) 2020 targets of at least 90% coverage across all 
childhood vaccines by 2019; and analyse the relationships 
between national-level vaccine coverage and sociodemographic 
development.
Implications of all the available evidence
Over the past four decades, global coverage of both 
longstanding and more newly available vaccines improved, and 
the number of zero-dose children declined by nearly 75% since 
1980. Yet from 2010 to 2019, much of the world saw progress 
stagnate or even reverse course. Most locations fell below the 
2020 GVAP target of achieving at least 90% coverage across 
vaccines in 2019, signalling the need to further expand 
programme reach of unvaccinated or under-vaccinated children. 
Associations between sociodemographic development and 
vaccine coverage varied, underscoring the importance of how 
vaccine programmes operate and reach target populations 
above and beyond development alone. Continuing to 
strengthen vaccine data systems and measurement 
approaches—and leveraging these inputs to inform programme 
investments and implementation—is crucial to ensure that all 
children have access to lifesaving vaccines.
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Drawing from the Global Burden of Diseases, 
Injuries, and Risk Factors Study (GBD) 2020, Release 1 
(GBD 2020 R1), we estimated coverage for 11 vaccine-
dose combinations in 204 countries and territories 
from 1980 to 2019. These include the well established 
original EPI vaccines (diphtheria-tetanus-pertussis, 
first dose [DTP1] and third dose [DTP3] vaccines; 
measles-containing vaccine, first dose [MCV1]; BCG, 
first dose; and polio vaccine, third dose [Pol3]), alongside 
newer vaccines introduced into national immunisa-
tion schedules over the past four decades (hepatitis B 
vaccine, third dose [HepB3]; Haemophilus influenzae 
type b vaccine, third-dose [Hib3]; measles-containing 
vaccine, second dose [MCV2]; pneumococcal conjugate 
vaccine, third dose [PCV3]; rubella-containing vaccine, 
first dose [RCV1]; and completed rotavirus series, 
two or three doses [RotaC]). We utilised survey and 
administrative data on vaccine coverage via a multi-
step modelling approach that includes bias adjustments 
for discordance between survey data and administrative 
data, and propagated uncertainty through each 
estimation step. Last, we did secondary analyses to 
further examine relationships between changes in 
sociodemographic development and vaccine coverage, 
and explored trends in those children who never received 
a DTP dose (referred to as zero-dose children,9,18,19 
proxying for children currently not reached by routine 
immunisation programmes). This study offers a crucial 
benchmark for global patterns in vaccine-specific and 
overall childhood vaccination trends before COVID-19, 
strengthening our collective understanding of past 
progress and challenges as the world pursues greater 
equity in immunisation access and delivery. This report 
was produced as part of the GBD Collaborator Network 
and in accordance with the GBD protocol.
Methods
Overview
This analysis is part of the broader GBD 2020 R1, an 
update from GBD 2019.20–22 The Global Health Data 
Exchange (GHDx) will be updated simultaneously with 
the release of new GBD rounds; content in these 
resources will always be synchronous. This analysis 
complies with the Guidelines for Accurate and 
Transparent Health Estimates Reporting (GATHER) 
statement,23 with further information provided in the 
appendix (section 1). All data processing and modelling 
were done in R statistical software, with more details 
provided in the appendix (sections 2–4) by analytical step; 
the source code will be made accessible upon publication 
and data are available on the GHDx website.
Data
We defined vaccine coverage as the proportion of 
children who received at least the stated vaccine dose 
(eg, DTP1) through a routine immunisation pro-
gramme; we excluded campaign doses when possible. 
Of 3118 total sources reviewed, 975 unique sources 
from 1980 to 2019 were used in this analysis, resulting 
in 55 326 country-cohort-year-vaccine-dose-specific 
data points across vaccines (appendix; tables S1–S3). 
We primarily used the GHDx to collate available 
coverage data sources as described in the appendix 
(sections 2.1–2.3; figure S2). These sources included 
household surveys (eg, Demographic and Health 
Surveys, Multiple Indicator Cluster Surveys, other 
multi-country survey series, and country-specific 
surveys) and official country-reported coverage data 
from the JRF. We excluded sources without data on 
children aged 12–59 months (aside from country-
reported data, which reflect target population ages) and 
sources that were not nationally representative (ie, 
geographically or focused on a subgroup of the target 
population) or did not include dose-specific vaccine 
coverage from at least one vaccine in or after the 
country-reported national introduction year. We then 
reviewed all vaccine coverage observations from sources 
meeting these criteria and excluded data obtained 
before introduction of each vaccine or judged to be 
implausible. Complete inclusion and exclusion criteria 
and details about all reviewed data sources are 
summarised in the appendix (section 2.3; figure S2, 
tables S1–S3). For survey data, children with either 
home-based records or parental recall indicating 
vaccine receipt were considered vaccinated. Where 
individual-level microdata were available, we estimated 
coverage as the proportion of vaccinated children by 
vaccine, dose, and age in years, accounting for survey 
design (appendix section 2.4). We extracted survey 
report tabulations if microdata were unavailable.
Age-cohort-specific coverage data from children aged 
12–59 months were assigned to the year of expected 
vaccine receipt using country-specific vaccine schedules 
and vaccine introduction years reported through the 
JRF.24,25 This approach aligns survey-based coverage 
estimates with those from country-reported data by 
cohort, facilitating adjustment for administrative bias.
Administrative bias adjustment
To incorporate administrative data while accounting for 
potential biases,26 we implemented bias adjustments for 
official country-reported data from the JRF for DTP3, 
MCV1, BCG, and Pol3. We first estimated the magnitude 
of potential bias by location-year, using paired obser-
vations of survey-based coverage estimates and JRF 
data for the same year, vaccine, location, and target 
population cohort. We then modelled administrative 
bias using a multi-step approach: we first predicted bias 
using the Healthcare Access and Quality (HAQ) Index 
(a summary measure of health-care performance27) as a 
covariate in a two-stage random spline model, and then, 
for locations with available bias observations, we used 
spatiotemporal Gaussian process regression (ST-GPR)20 
to better account for trends in bias (appendix section 3.4).
See Online for appendix
For the Global Health Data 
Exchange see http://ghdx.
healthdata.org
For more on Demographic 
and Health Surveys see 
https://dhsprogram.com/
For more on Multiple Indicator 
Cluster Surveys see https://mics.
unicef.org/
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Vaccine-specific coverage estimation
We modelled vaccine-specific coverage using ST-GPR,20 a 
statistical method that enables non-linear trend estimation 
and incorporates data uncertainty into final estimates 
(appendix section 3.2). We used the HAQ Index and GBD 
mortality estimates from conflict and terrorism per capita 
as covariates in the first stage of each model, along with a 
covariate based on country-reported stockouts or other 
disruptions derived from discontinuities in administrative 
data (appendix section 3.7).
Relative to DTP3, country-reported data on DTP1 were 
sparse or not routinely collected from 1980 to 2000. We 
developed a time-varying model to impute DTP1 from 
reported DTP3 coverage and trends in DTP1–3 dropout, 
and used continuation-ratio ordinal regression to ensure 
internal consistency between DTP1 and DTP3 for the full 
time period (appendix section 3.3).28
Since more recently introduced vaccines had 
comparatively less available data, we used the more 
data-rich DTP3 and MCV1 models to inform estimation of 
HepB3, Hib3, PCV3, RotaC, MCV2, and RCV1 coverage 
(appendix section 3.6). We modelled the coverage ratio 
of newer vaccines relative to reference vaccines (DTP3 
or MCV1) on the basis of schedule similarity, using 
observations from both survey data and unadjusted 
country-reported data. We used ST-GPR to estimate full 
time series for each scale-up ratio, then multiplied these 
ratios by corresponding DTP3 or MCV1 estimates to 
produce final estimates for all newer vaccines while 
propagating uncertainty.
We assumed 0% coverage for each vaccine before 
its formal introduction in national immunisation 
schedules, with the exception of Hib3, PCV3, and 
RotaC in China. For these vaccines, which were 
available in private markets but not yet included in the 
national immunisation schedule, we constrained 
estimates using lot release data (China National 
Institutes for Food and Drug Control29 and Y Teng, 
Linksbridge SPC, personal communication); further 
details are provided in the appendix (section 3.8). For 
DTP3, MCV1, BCG, and Pol3, we used EPI onset 
information to indicate the introduction of these 
vaccines and assumed no children were vaccinated with 
these vaccines before their formal introduction. Where 
applicable (eg, for BCG), we also assumed 0% coverage 
for eligible cohorts after removal of a vaccine from 
national immunisation schedules.
To compute 95% uncertainty intervals (UIs) for 
location-year-vaccine estimates, we sampled 1000 random 
draws from the modelled posterior distribution and 
took the ordinal 2·5th and 97·5th percentile of draws 
for each measure. National estimates were aggregated 
to GBD super-regions, groupings based on geo-
graphical proximity and epidemiological similarity,30 
using GBD 2020 R1 estimates of target age group 
populations (updated from GBD 201922 as part of the 
GBD continuous update cycle).
Assessing coverage trends in relation to 
sociodemographic development, GVAP target 
attainment, and zero-dose children
Using these coverage estimates, we did three additional 
analyses. First, we sought to examine relationships 
between vaccine coverage and sociodemographic develop-
ment, a type of benchmarking exercise used to identify 
potential performance outliers and where improvements 
in health are occurring faster or more slowly than parallel 
changes in development.22,31,32 For our development 
metric we used the GBD’s Socio-demographic Index 
(SDI), a summary measure on a scale of 0–100 based on 
average income per capita, educational attainment, and 
fertility rates in a given location and year.22 We applied a 
constrained mixed-effects meta-regression33 to quantify 
global averages of expected coverage—estimated levels 
for any value of SDI—for DTP3, MCV1, and Pol3 across 
all location-years. We then compared country-level 
vaccine coverage and SDI estimates from 1980 to 2019 
relative to these global averages of expected coverage on 
the basis of SDI alone. Further details are provided in the 
appendix (section 4.1).
Second, we evaluated progress towards the 2020 GVAP 
target of at least 90% national-level coverage across 
vaccines.7 We defined target attainment as a mean 
coverage estimate of 90% or higher, by vaccine and 
for all assessed vaccines, in 2010 and 2019. To ensure 
comparability across vaccines and years, our main ana-
lysis included nine vaccines for each location and year, 
irrespective of vaccine introduction. We then repeated 
this analysis considering only vaccines included in each 
location’s national immunisation schedule in the year of 
evaluation (appendix section 4.2).
Third, we estimated the number of zero-dose children 
as a function of DTP1:
where DTP0 is the number of children younger than 
1 year of age without any DTP doses for location i and 
year y, DTP1 is DTP1 coverage, and p is the GBD 2020 
R1 population estimate of children younger than 1 year. 
We used children who did not receive a first dose of 
a DTP-containing vaccine as a proxy for zero-dose 
children not reached by routine immunisation services, 
following the draft IA2030 implementation framework 
(which has since been published)9 and previous 
studies;18 additional details are provided in the appendix 
(section 4.3).
Comparison with WUENIC estimates
We calculated concordance correlation coefficients for 
each vaccine, comparing coverage estimates to those 
produced by WUENIC for each location-year. We also 
aggregated country-level WUENIC coverage estimates to 
the global level (weighted means using GBD 2020 R1 
target population estimates, to provide more direct 
DTP0iy=(1 – DTP1iy) × piy
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comparisons with this study’s global estimates; appendix 
section 4.4, table S8).
Role of the funding source
The funder of this study had no role in study design, data 




In this section, we present global results and results by 
GBD super-region. Owing to BCG phase-out or non-
introduction in 46 countries as of 2019, the results 
presented here focus on the remaining vaccines. We 
present DTP3 coverage estimates for consistency with 
other vaccines delivered as a three-dose primary series, 
while using DTP1 coverage to estimate counts of zero-dose 
children. Coverage estimates by vaccine, including BCG 
and DTP1, are available for each location from 1980 to 2019, 
with corresponding WUENIC estimates, in the appendix 
(figures S18–S28, S31, table S7) and on the GHDx website.
Historical trends and progress in routine vaccination
Globally, vaccine coverage markedly increased from 
1980 to 2019 (figure 1). MCV1 coverage more than 
doubled, rising from 38·5% (95% UI 35·4–41·3) in 1980 
to 83·6% (82·3–84·8) in 2019. During this time, 
DTP3 coverage also increased from 39·9% (37·5–42·1) 
to 81·6% (80·4–82·7), and Pol3 coverage rose from 
42·6% (41·4–44·1) to 79·8% (78·4–81·1).
Overall, progress for these routine vaccines was most 
rapid from 1980 to 1989 (figure 2). For DTP3 specifically, 
global coverage increased from 39·9% (95% UI 
37·5–42·1) to 64·2% (63·3–65·1). All GBD super-regions 
saw DTP3 coverage rise, with universal country-level 
gains in Latin America and the Caribbean, north Africa 
and the Middle East, and south Asia. These improvements 
were concentrated among locations starting with lower 
coverage: for instance, of 123 countries with DTP3 
coverage lower than 60% in 1980, 106 (86·2%) had more 
than a ten-percentage-point gain by 1989. Similar 
patterns occurred in the next two decades, with 
19 (48·7%) of 39 countries with DTP3 coverage lower 
than 60% increasing by at least ten percentage points 
from 1990 to 1999, as did 26 (76·5%) of 34 countries 
from 2000 to 2009.
From 2010 to 2019, however, progress on DTP3, 
MCV1, and Pol3 coverage stalled or reversed in many 
locations. For DTP3, 25 countries with at least 
90% coverage in 2010 saw levels fall below this 
threshold in 2019, and 16 countries with coverage 
ranging from 60% to 90% in 2010 saw declines of 
five percentage points or more by 2019. Globally, 
94 countries and territories recorded decreasing DTP3 
coverage since 2010, with countries in Latin America 
and the Caribbean among those with the largest 
reductions (figure 2; appendix figure S14). Results were 
similar for MCV1 and Pol3 coverage (appendix 
figure S14).
Introduction and scale-up of newer vaccines
Since the early 2000s, vaccines such as HepB, Hib, 
MCV2, PCV, RCV, and RotaC were introduced into 
many countries’ national immunisation schedules and 
scaled up in an effort to expand protection against these 
vaccine-preventable diseases. By 2019, global coverage 
of these newer additions began to approach that of 
more established vaccines, reaching 80·7% (95% UI 
79·5–81·8) for HepB3, 70·6% (69·2–71·9) for Hib3, 
69·5% (68·6–70·3) for RCV1, and 68·1% (66·5–69·5) 
for MCV2 (figure 1). Although global PCV3 and 
RotaC coverage were somewhat lower in 2019 (47·9% 
[47·0–48·9] and 39·1% [38·0–40·4], respectively), 
countries that introduced these vaccines often rapidly 
increased coverage. For instance, of the 125 countries 
that introduced PCV into their routine immunisation 
schedules before 2015, 104 (83·2%) reached PCV3 
coverage within five percentage points of DTP3 coverage 
by 2019; 57 (45·6%) of 79 achieved the equivalent for 
RotaC coverage.
Progress towards GVAP targets
Benchmarking country performance from 2010 to 2019 
provides insight into GVAP trajectories and the likelihood 
of achieving the 2020 target (figure 3). In 2010, 
121 (59·3%) of 204 countries and territories reached at 
least 90% mean coverage for DTP3, as did 120 (58·8%) of 
204 countries and territories for MCV1, and 117 (57·4%) 
of 204 countries and territories for Pol3; by contrast, 
in 2019, 109 (53·4%) of 204 countries and territories 
reached at least 90% mean coverage for DTP3, as did 
124 (60·8%) of 204 countries and territories for MCV1, 
and 109 (53·4%) of 204 countries and territories for Pol3. 
Figure 1: Global vaccine coverage by vaccine, 1980–2019
The dotted line represents the GVAP target of reaching at least 90% coverage by 2020. The solid lines represent the 
mean estimates for each vaccine. The lighter-coloured shading surrounding the solid lines represents the 
95% uncertainty intervals. GVAP=Global Vaccine Action Plan. DTP1=diphtheria-tetanus-pertussis vaccine, first dose. 
DTP3=diphtheria-tetanus-pertussis vaccine, third dose. HepB3=hepatitis B vaccine, third dose. Hib3=Haemophilus 
influenzae type b vaccine, third dose. MCV1=measles-containing vaccine, first dose. MCV2=measles-containing 
vaccine, second dose. PCV3=pneumococcal conjugate vaccine, third dose. Pol3=polio vaccine, third dose. 
RCV1=rubella-containing vaccine, first dose. RotaC=completed rotavirus series.
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Worsening performance was particularly striking for 
two GBD super-regions (central Europe, eastern Europe, 
and central Asia; and Latin America and the Caribbean), 
whereas south Asia saw sustained improvement for 
MCV1. Sub-Saharan Africa had the lowest proportion of 
countries that met the 90% mean GVAP target in 2019, 
Figure 2: Changes in DTP3 coverage, by decade, from 1980 to 1989 (A), 1990 to 1999 (B), 2000 to 2009 (C), and 2010 to 2019 (D)
For each decade, maps (left) and scatterplots (right) are colour-coded to reflect absolute changes in DTP3 coverage. Locations not estimated for GBD are shown in grey. 
Each circle on the scatterplot represents a country or territory, and the same colour is reflected on the corresponding map. For the scatterplots, the horizontal dashed line 
at 0 indicates no coverage change within the decade; the vertical dashed lines mark 60% and 90% coverage, with the latter being the national GVAP target for 2020. 
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ranging from 2·2% to 32·6% by vaccine, and with 
19 (41·3%) of 46 locations meeting this mean target 
for any vaccine. Globally, 11 countries and territories 
reached 90% or higher average coverage across nine 
assessed vaccines in 2019: Armenia, Australia, Bahrain, 
Mauritius, Morocco, Nicaragua, Niue, Norway, Palestine, 
Qatar, and Saudi Arabia. Target attainment conditional 
on vaccine introduction is summarised in the appendix 
(figure S29).
Changes in vaccine coverage relative to 
sociodemographic development
On average, higher vaccine coverage was associated with 
higher SDI (figure 4); however, this relationship was far 
from linear. For instance, an increase in SDI values 
from 25 to 35 (on a 0–100 scale) was associated with a 
greater than 25-percentage-point difference in DTP3 
coverage (ie, from expected global averages of 30·3% 
[95% UI 27·7–32·8] with an SDI of 25 to 58·5% 
[55·0–61·5] with an SDI of 35). At higher levels of SDI, 
similar changes in SDI were associated with far 
less pronounced changes in coverage: changing from 
an SDI of 75 to 85, for example, corresponded to a 
2·0-percentage-point difference in DTP3 coverage (from 
95·3% [94·7–95·8] to 97·3% [97·0–97·6]).
Comparing these average global relationships between 
DTP3 coverage and SDI also helps to identify locations 
that have outpaced—or are lagging behind—changes in 
development. Burkina Faso, for example, emerged as far 
exceeding its expected DTP3 coverage given its SDI, 
reaching 92·4% (87·3–95·9) coverage in 2019 when its 
expected DTP3 coverage was 35·6% (32·9–38·2) relative 
Figure 3: Percentage of locations reaching the GVAP national coverage target in 2010 and 2019, globally and by GBD super-region
Each cell represents the percentage of locations, globally and by GBD super-region, that have reached the GVAP 90% national coverage target in 2010 and 2019 for 
the assessed vaccines. Percentages are shown for each vaccine separately meeting the target, for at least any single vaccine meeting the target, and for all assessed 
vaccines listed as meeting the target. Percentages are calculated on the basis of the total number of locations in the GBD super-region, irrespective of whether 
locations included the vaccine in their national schedule in 2010 or 2019. GVAP=Global Vaccine Action Plan. GBD=Global Burden of Diseases, Injuries, and Risk Factors 
Study. DTP3=diphtheria-tetanus-pertussis vaccine, third dose. MCV1=measles-containing vaccine, first dose. Pol3=polio vaccine, third dose. HepB3=hepatitis B 
vaccine, third dose. Hib3=Haemophilus influenzae type b vaccine, third dose. MCV2=measles-containing vaccine, second dose. RCV1=rubella-containing vaccine, 
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Figure 4: Relationships between national DTP3 coverage and SDI, 1980–2019
The solid red line represents the global average relationship between DTP3 coverage and SDI alone, as estimated 
across locations and over time; the shading represents the 95% uncertainty interval. Observed SDI estimates and 
DTP3 coverage estimates for each location are shown in light grey. For selected countries (ie, Burkina Faso, India, and 
Angola), the colour of each point represents the estimation year, from yellow (1980) to purple (2019). Each location’s 
vaccine coverage estimates relative to SDI can be found in the appendix (figure S15). DTP3=diphtheria-tetanus-
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to SDI. By contrast, Angola had among the largest gaps 
between estimated DTP3 coverage and expected levels on 
the basis of SDI alone: in 2019, Angola’s DTP3 coverage 
was 40·3% (33·7–47·3), whereas its expected coverage 
was 81·6% (79·6–83·3). While this gap grew in Angola 
over time, by 2019 other countries such as India saw 
observed coverage track more closely to expected 
estimates on the basis of SDI alone. Similar patterns 
occurred for MCV1 and Pol3 coverage, with country-by-
country comparisons for each vaccine provided in the 
appendix (figures S15–S16).
Trends in the number of zero-dose children
Globally, the number of zero-dose children fell from 
56·8 million (95% UI 52·6–60·9) in 1980 to 14·5 million 
(13·4–15·9) in 2019, a decrease of nearly 75% (figure 5). 
Southeast Asia, east Asia, and Oceania had among the 
largest reductions during this time (86·3% [83·0–89·1]), 
as did south Asia (84·4% [78·3–89·1]). Trends in counts 
of zero-dose children involved both changes in DTP1 
coverage and population growth. For example, in 
sub-Saharan Africa, the total number of zero-dose 
children decreased by 30·1% (21·8–37·8) from 1980 
to 2019, with 6·5 million (5·8–7·1) zero-dose children 
remaining in 2019. Yet the percentage of zero-dose 
children in sub-Saharan Africa decreased even more 
drastically, from 57·1% (54·1–59·9) in 1980 to 18·6% 
(16·8–20·5) in 2019. Conversely, the number and 
proportion of zero-dose children increased in Latin 
America and the Caribbean from 2000 onwards, rising 
from 0·52 million (0·46–0·58) in 2000 to 1·5 million 
(1·2–1·7) in 2019 and from 5·0% (4·4–5·6) in 2000 
to 15·6% (13·2–18·1) in 2019. In 2019, 75% of zero-dose 
children lived in 14 countries: Angola, Brazil, Chad, 
China, Democratic Republic of the Congo, Ethiopia, 
India, Indonesia, Mexico, Nigeria, Pakistan, Philippines, 
Somalia, and South Africa.
Comparison with WUENIC estimates
Concordance between GBD-based and WUENIC-based 
estimates was generally high (ie, from ρc=0·74 for RCV1 
to ρc=0·92 for DTP3 and MCV1; appendix table S8). 
Globally, similar coverage trends were observed for 
DTP3, MCV1, and Pol3, with gains stagnating from 2010 
to 2019,13,18 and more variation occurred at the country 
level, as well as by vaccine, over time. Additional com-
parisons are shown in the appendix (figures S30–S31).
Discussion
Summary of the main findings
This study provides a comprehensive assessment of 
global patterns in coverage for 11 vaccines from 1980 
to 2019, a 40-year period of both notable progress and 
enduring disparities for routine vaccination. Coverage of 
longstanding and more recently introduced vaccines 
improved in much of the world between 1980 and 2010, 
protecting more children against vaccine-preventable 
diseases than ever before. Yet from 2010 to 2019, a period 
in which the introduction and scale-up of new vaccines 
was largely successful, gains for more established 
vaccines were minimal; in some locations, particularly in 
Latin America and the Caribbean, vaccine coverage 
faltered. These trends imply that, while the GVAP era 
broadened global access to more vaccines, less progress 
was made in ensuring routine immunisation services 
reach all children. In 2019, 14·5 million children 
worldwide still lacked one dose of DTP, a key indicator of 
zero-dose children and thus those who are at greatest risk 
of being left behind. Timely, disaggregated data on the 
evolving needs for routine immunisation programmes 
Figure 5: Proportion (A) and total number (B) of zero-dose children, globally and by GBD super-region, 1980–2019
The solid lines represent the proportion of zero-dose children for each GBD super-region, and the lighter-coloured shading surrounding the solid lines represents the 
95% uncertainty intervals. Zero-dose children are approximated by subtracting estimates of DTP1 coverage from 100%, and then multiplying percentages by 
population estimates from GBD. Bar colours denote each GBD super-region. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. DTP1=diphtheria-
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are crucial to target resources to those who need them the 
most, particularly if the global ambitions encompassed by 
IA2030 are to be realised in the next decade.
Global gains and challenges in routine immunisation
The GVAP era followed years of sizeable progress 
for childhood vaccination: from 1980 to 2010, global 
coverage of original EPI vaccines such as DTP3 and 
MCV1 more than doubled, the number of zero-dose 
children fell steadily, and from the early 2000s initiatives 
such as Gavi, the Vaccine Alliance, supported the 
introduction and scale-up of new vaccines.18,19,34 Access to 
HepB and Hib vaccines, as well as PCV and RotaC, 
vastly improved, and many countries, especially those in 
sub-Saharan Africa, rapidly increased coverage of these 
newer vaccines to approach that of more established 
vaccines. Yet expanding these gains hinges upon 
increasing the reach of routine immunisation to all 
children—and the world has been far less successful 
in this endeavour, as evidenced by the stagnating or 
even faltering coverage of long-established vaccines 
between 2010 and 2019. Such trends correspond with 
other global analyses, such as those from WUENIC, 
underscoring challenges in further improving and 
expanding vaccine coverage in the past decade.18,19 
Although countries across the sociodemographic 
spectrum have shown these concerning trends, this 
trajectory has been particularly striking for Latin 
America and the Caribbean. Past research suggests 
that compounding factors, including large subnational 
disparities in access to vaccines and shifting perceptions 
of vaccine risk, could have contributed to regional 
declines.35–37 By 2019, only 109 of 204 countries and 
territories reached at least 90% mean estimated coverage 
for DTP3, while only 11 countries and territories met this 
threshold across nine of the assessed vaccines.
Improving and sustaining advances in vaccination 
requires a constellation of local and global factors, and our 
analysis further emphasises that progress in routine 
immunisation is far from inevitable. Key determinants 
that drive childhood vaccination trends are complex and 
inter-related, ranging from individual and community-
level characteristics (eg, parental knowledge, vaccine 
confidence, and physical and financial access to 
immunisation services) to health-system capacity and 
enabling macro-level forces (eg, general health-system 
strength, political commitment to vaccine programmes, 
reliable funding, and supportive policies).38,39 Longstanding 
challenges in supply chain or distribution channels can 
constrain further scale-up and outreach services,40 while 
societal vaccine confidence patterns have been strongly 
linked to uptake.41 Prolonged conflict or surges of unrest 
can contribute to persistently low coverage or abrupt 
declines in vaccination rates.42,43 Widespread infectious 
disease outbreaks, as underscored by Ebola virus disease 
and now COVID-19,44,45 can strain already fragile health 
systems and disrupt usual modes of vaccine delivery. How 
these factors affect vaccine services differs across locations 
and over time, and thus warrants further examination to 
better understand the pathways towards strengthening 
routine immunisation services.
In light of recent trends, coupled with the effects 
of COVID-19 on routine immunisation services,10–12 
accelerating global vaccination gains will require more 
than a continuation of current programme strategies.41,42 
By quantifying uncertainty and synthesising multiple 
sources of coverage data while adjusting for biases, 
statistically derived coverage estimates provide a robust 
platform to track progress towards global targets. More-
over, IA2030 marks an evolution in global immunisation 
priorities, recognising the limitations of the more top-
down GVAP46 and championing locally tailored approaches 
for each community. IA2030 also emphasises the need to 
identify and reach zero-dose children historically missed 
by routine immunisation services, and that strengthening 
of such services must occur in tandem with bolstering 
service access and primary care integration.47 To support 
these efforts, the action-based IA2030 Monitoring and 
Evaluation Frame work supports the use of data not only to 
track progress but also to continuously improve routine 
immunisation programmes at all levels of implementa-
tion.9 This shift in strategy aims to further develop the 
reach, equity, and sustainability of global immunisation 
systems within the contexts of primary care and universal 
health coverage. For these efforts to be successful, 
however, data must be of sufficient quality to inform 
policy decisions. As such, our estimates can serve as a 
useful comparator to those produced by WUENIC:48 areas 
of divergence might indicate low data availability or 
quality, resulting in high sensitivity to methodological 
assumptions.
Countries where coverage gains have outpaced the 
average pace of progress could provide valuable insights 
for breaking through coverage plateaus. For example, 
studies of vaccine coverage in Burkina Faso emphasise 
the importance of leadership and communication from 
vaccination centres in promoting effective services.49,50 
Consistency in programme review, funding, and country-
led initiatives targeting traditionally marginalised or 
hard-to-reach populations has been positively asso ciated 
with vaccine uptake and success.51 Amid ongoing 
challenges to equitably improve routine immunisation, 
our estimates of vaccine coverage aim to augment the 
evidence base from which more data-driven and strategic 
planning can occur for global initiatives and national 
programmes alike.
Limitations
This study is subject to several limitations. First, we 
could not account for all potential sources of bias in 
survey data. For example, displaced or otherwise 
marginalised populations could be under-represented in 
surveys that base sampling frames on official census 
data. Parental recall of vaccination is also subject to bias. 
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We did not apply a recall adjustment, as previous efforts 
to quantify recall biases show substantial variation in 
both direction and magnitude.52–54 We were also unable to 
systematically adjust for differences in methodological 
quality between surveys, as such descriptions were not 
available for all sources. Second, our approach to 
leveraging multiple age cohorts maximises the use of 
available data, but assumes negligible effects of 
migration, survival bias due to differential mortality by 
vaccination status, and catch-up vaccination that might 
not be well captured in survey data. These limitations 
could result in over-estimation of coverage in some 
locations (ie, marginalised groups generally have lower 
access to routine immunisation services than the general 
population; unvaccinated children might have higher 
mortality at young ages than vaccinated children and 
thus are not represented in survey data); however, the 
precise effects are likely to vary by location and over time. 
Third, in order to incorporate both administrative and 
survey data into our current modelling framework, we 
did not account for the timeliness of vaccination. Future 
studies should develop methods to estimate age-specific 
coverage rates where data permit, as such estimates 
could better reflect trends in schedule adherence and 
when delays in vaccination are occurring. Fourth, our 
estimates do not explicitly account for vaccines 
administered through private markets (aside from 
selected vaccines in China), vaccines introduced only for 
certain at-risk populations, or vac cine doses administered 
through campaigns; as such, coverage might be under-
estimated in locations where these modes of delivery are 
common. Fifth, although also utilised elsewhere,9,18 using 
DTP1 coverage to inform zero-dose estimates could over-
estimate the total number of children who have never 
received any vaccine. Future analyses could examine the 
correlation structures across vaccine-dose combinations 
at the individual level and ascertain the likelihood of 
children without DTP1 receiving any other vaccine over 
time.55 Sixth, our study focuses on national-level vaccine 
coverage, which might obscure important subnational 
inequalities.56,57 To reach children left behind by current 
vaccination programmes, within-country disparities in 
childhood vaccination coverage across factors trans-
cending geography (eg, wealth and education, race and 
ethnicity, and refugee status) must continue to be 
identified and addressed.
Conclusions
Childhood vaccine coverage has markedly improved 
since the 1980s, cementing efforts to expand original EPI 
vaccines and initiatives to scale up new vaccines as 
among the most important success stories in global 
health. Yet, stagnation and, in some cases, reversal of 
gains from 2010 to 2019 serve as warning signs that 
staying the course today will not deliver universal access 
to immunisation in the future. The complementary 
visions of GVAP and now IA2030 conceive of a world 
where all children benefit from the protection of safe and 
effective vaccines and have the opportunity to live full, 
healthy lives. To meet these goals, it is crucial to address 
both enduring and new challenges facing childhood 
vaccination efforts and use evidence-informed strategies 
for strengthening routine immunisation programmes 
throughout the world.
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